Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RenovoRx, Inc. filings document the regulatory record of a life-sciences company commercializing RenovoCath® and developing targeted oncology therapies through its TAMP™ platform. Periodic and current reports disclose operating results, commercialization updates, clinical-trial strategy, and business updates related to the company’s investigational IAG drug-device candidate.
The company’s SEC record includes 8-K filings for financial results, material agreements, equity financings, warrant instruments, and at-the-market offering arrangements. Proxy materials cover annual meeting matters, board governance, executive compensation, and shareholder voting items, while leadership-related filings document officer appointments, compensatory arrangements, and reporting responsibilities.
RenovoRx, Inc. (Nasdaq: RNXT) filed a Form 8-K to report the voting results of its 2025 Annual Meeting held on 24 June 2025. Of the 36,551,752 shares outstanding on the 25 April 2025 record date, approximately 20,086,518 shares (55%) were present or represented by proxy, satisfying quorum requirements.
Proposal 1 – Director Elections: All seven nominees were elected to one-year terms expiring at the 2026 meeting. Four directors (Bagai, Agah, Macfarlane) received ~13.0 million votes each with minimal withholds, while three directors (Marton, Ryan, Spiegel) received ~9.5-9.9 million votes and ~3.3-3.6 million withholds. Broker non-votes were 6.95 million for every nominee.
Proposal 2 – Equity Incentive Plan Amendments: Shareholders approved (i) reserving an additional 913,794 shares (2.5% of outstanding) for the 2021 Omnibus Equity Incentive Plan and (ii) raising the plan’s evergreen provision from 3% to 5% of year-end shares. Votes: 9,056,181 for; 4,037,698 against; 38,379 abstentions; 6,954,260 broker non-votes.
Proposal 3 – Auditor Ratification: Frank, Rimerman + Co. LLP was ratified as independent auditor for FY 2025 with strong support (19,131,750 for; 949,070 against; 5,698 abstentions).
The filing discloses no financial performance metrics or strategic transactions but confirms routine corporate governance matters, an expanded share reserve for equity compensation, and continuity of external audit oversight.